Skip to content

A Multicenter Randomized Controlled Trial to Evaluate the Efficacy and Safety of Treatment Based on Syndrome Differentiation Combined with Chinese Herb Power in Patients with Chronic Gastritis with Erosion

Applied research on norms of Traditional Chinese medicine diagnosis and treatment in view of the refractory spleen and stomach diseases (Chronic gastritis part)

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15005905
Enrollment
Unknown
Registered
2015-01-22
Start date
2015-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic gastritis

Interventions

A1:Chinese Herb decoction+powder1
A2:Chinese Herb decoction+powder2
Control:Almagate

Sponsors

Xiyuan Hospital Affiliated to China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet diagnostic criteria of chronic atrophic gastritis; 2. To be aged 18-70 years old; 3. over grade ?gastric erosions, with erythema or mucosal bleeding 4. with any symptom of early satiation, postprandial fullness, epigastric pain, epigastric burning; 5. sign the informed consent and will accept the corresponding treatment.

Exclusion criteria

Exclusion criteria: 1. Patients with Helicobacter pylori infection; 2. Patients with chronic atrophic gastritis accompany with severe dysplasia, upper gastrointestinal hemorrhage peptic ulcer, gastroenteric tumor; 3. Patients with Gastrointestinal organic diseases(such as chronic pancreatitis, hepatic cirrhosis,etc) or systemic diseases which can affect gastrointestinal power(such as hyperthyroidism?diabetes mellitus, chronic renal insufficiency, mental diseases and nerve system diseases etc); 4. Patients with severe heart, hepatic, renal diseases, hematopoietic diseases, and tumor; 5. except the study drugs, patients need to use the drugs which will affect the gastrointestinal function(such as H2RA, PPI, gastric mucosa protectant, acid-inhibitory drugs, prokinetic agents, anticholinergic drugs, etc. or have similar effect of traditional Chinese medicine; 6. With drinking history in nearly a week; 7. Pregnant and Lactating women; 8. With the history of mental or nerve system diseases; 9. With the history of allergic reaction to used drugs; 10. Patients who have participated in other clinical trials.

Design outcomes

Primary

MeasureTime frame
The improvement of the gastric mucosal erosion under gastroscope;The improvement of histopathology presentations of Acute and chronic inflammation and atrophy;

Secondary

MeasureTime frame
Symptom score;Patients Report Outcomes score;Safety index;

Countries

China

Contacts

Public ContactTang Xudong
txdly@sina.com+86 010-62835001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026